What is the price target for SIBN stock?
15 analysts have analysed SIBN and the average price target is 25.65 USD. This implies a price increase of 114.97% is expected in the next year compared to the current price of 11.93.
NASDAQ:SIBN • US8257041090
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SI-BONE INC (SIBN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-15 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-24 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-24 | Truist Securities | Reiterate | Buy -> Buy |
| 2026-01-27 | TD Cowen | Initiate | Buy |
| 2025-12-18 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-16 | Needham | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-15 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-06 | Needham | Reiterate | Buy -> Buy |
| 2025-05-06 | Truist Securities | Maintains | Buy -> Buy |
| 2025-02-25 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-25 | Needham | Maintains | Buy -> Buy |
| 2025-02-25 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-20 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | Truist Securities | Maintains | Buy -> Buy |
| 2024-10-14 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-06 | Needham | Maintains | Buy -> Buy |
| 2024-08-06 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 138.886M 30.53% | 167.178M 20.37% | 200.925M 20.19% | 234.99M 16.95% | 270.07M 14.93% | 311.46M 15.33% | 357.2M 14.69% | 408.1M 14.25% | |
| EBITDA YoY % growth | -41.503M 26.09% | -30.869M 25.62% | -16.56M 46.35% | 10.232M 161.79% | 19.073M 86.41% | 34.881M 82.88% | 55.896M 60.25% | 76.806M 37.41% | |
| EBIT YoY % growth | -46.931M 21.26% | -35.248M 24.89% | -22.33M 36.65% | -25.711M -15.14% | -21.176M 17.64% | -11.557M 45.42% | 3.978M 134.42% | 19.686M 394.87% | |
| Operating Margin | -33.79% | -21.08% | -11.11% | -10.94% | -7.84% | -3.71% | 1.11% | 4.82% | |
| EPS YoY % growth | -1.14 36.31% | -0.76 33.33% | -0.44 42.11% | -0.53 -19.72% | -0.42 20.24% | -0.27 36.88% | 0.05 119.23% | 0.33 540.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.19 -28.52% | -0.17 -17.87% | -0.12 -12.30% | -0.05 -17.02% | -0.14 26.28% | -0.12 25.62% | -0.11 11.92% | -0.05 -9.68% |
| Revenue Q2Q % growth | 52.128M 10.23% | 57.026M 17.27% | 57.108M 17.37% | 68.726M 21.96% | 63.376M 21.58% | 66.13M 15.96% | 66.334M 16.16% | 75.242M 9.48% |
| EBITDA Q2Q % growth | 57.559K 100.93% | 1.479M 133.94% | 2.649M 311.75% | 6.061M 83.28% | 4.462M 7,652.10% | 4.676M 216.16% | 5.067M 91.28% | 7.023M 15.87% |
| EBIT Q2Q % growth | -8.991M -20.20% | -7.763M -10.83% | -5.973M -10.95% | -2.561M -3.98% | -6.7M 25.48% | -6.485M 16.46% | -5.162M 13.57% | -2.548M 0.51% |
All data in USD
15 analysts have analysed SIBN and the average price target is 25.65 USD. This implies a price increase of 114.97% is expected in the next year compared to the current price of 11.93.
SI-BONE INC (SIBN) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of SI-BONE INC (SIBN) is -0.19 USD and the consensus revenue estimate is 52.13M USD.
The consensus rating for SI-BONE INC (SIBN) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.